Kyriakides reiterated in the letter that the scaling up of the production capacity has to happen concurrently with the conduct of clinical trials to ensure the availability of the vaccines as quickly as possible. The European Medicines Agency has not yet given its authorization — a point that has led to criticism from EU states. Her spokesperson said that the scaling up of production was an important premise of the contract.
The issue will be discussed in a meeting of the steering board made up of the European Commission, member states and the company today (25 January) where it will be made clear that the EU expects contractual obligations to be met.
Chief Spokesperson for the European Commission Eric Mamer added that European Commission President had spoken with the CEO of Astra Zeneca, where she reminded him that the EU has invested significant amounts in scaling up production. However, she also recognized that production issues can appear with a complex vaccine.
Share this: Kyriakides calls on Astra Zeneca to respect delivery schedules for its vaccine
"Diario ilustrado". Una publicación electrónica independiente que apoya puntos de vista liberales, progresistas, Pro-europeos y Pro-empresariales. La publicación fue creada por un grupo de periodistas independientes en oposición a la línea mediática de Rupert Murdoch y publicaciones conservadoras y de derecha. Publicado en español